Victory Capital Management Inc. bought a new stake in shares of Eagle Pharmaceuticals Inc. (NASDAQ:EGRX) during the third quarter, according to its most recent 13F filing with the SEC. The fund bought 690,260 shares of the specialty pharmaceutical company’s stock, valued at approximately $48,318,000. Victory Capital Management Inc. owned 4.41% of Eagle Pharmaceuticals at the end of the most recent quarter.

Several other institutional investors have also added to or reduced their stakes in EGRX. Janus Capital Management LLC increased its stake in shares of Eagle Pharmaceuticals by 2.9% in the second quarter. Janus Capital Management LLC now owns 1,490,229 shares of the specialty pharmaceutical company’s stock valued at $57,805,000 after buying an additional 42,690 shares during the period. State Street Corp increased its stake in shares of Eagle Pharmaceuticals by 64.3% in the first quarter. State Street Corp now owns 629,493 shares of the specialty pharmaceutical company’s stock valued at $25,489,000 after buying an additional 246,262 shares during the period. BlackRock Fund Advisors increased its stake in shares of Eagle Pharmaceuticals by 0.6% in the second quarter. BlackRock Fund Advisors now owns 411,735 shares of the specialty pharmaceutical company’s stock valued at $15,971,000 after buying an additional 2,501 shares during the period. Vanguard Group Inc. increased its stake in shares of Eagle Pharmaceuticals by 3.1% in the second quarter. Vanguard Group Inc. now owns 362,609 shares of the specialty pharmaceutical company’s stock valued at $14,066,000 after buying an additional 10,933 shares during the period. Finally, Perceptive Advisors LLC increased its stake in shares of Eagle Pharmaceuticals by 60.2% in the second quarter. Perceptive Advisors LLC now owns 300,000 shares of the specialty pharmaceutical company’s stock valued at $11,637,000 after buying an additional 112,785 shares during the period.

Institutional Ownership by Quarter for Eagle Pharmaceuticals (NASDAQ:EGRX)

Shares of Eagle Pharmaceuticals Inc. (NASDAQ:EGRX) traded up 0.33% on Wednesday, hitting $78.40. 33,677 shares of the stock traded hands. Eagle Pharmaceuticals Inc. has a one year low of $33.02 and a one year high of $102.48. The stock has a 50 day moving average of $70.68 and a 200 day moving average of $56.92. The company has a market cap of $1.21 billion, a PE ratio of 51.04 and a beta of 1.37.

Eagle Pharmaceuticals (NASDAQ:EGRX) last posted its earnings results on Wednesday, November 9th. The specialty pharmaceutical company reported $0.73 EPS for the quarter, beating the Zacks’ consensus estimate of $0.61 by $0.12. Eagle Pharmaceuticals had a net margin of 20.06% and a return on equity of 25.63%. The company earned $37.80 million during the quarter, compared to analysts’ expectations of $41.04 million. During the same quarter in the prior year, the company posted ($0.65) earnings per share. Eagle Pharmaceuticals’s revenue for the quarter was up 563.2% compared to the same quarter last year. Equities analysts anticipate that Eagle Pharmaceuticals Inc. will post $4.59 earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: “Victory Capital Management Inc. Takes Position in Eagle Pharmaceuticals Inc. (EGRX)” was first reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this news story on another website, it was stolen and republished in violation of United States and international trademark and copyright legislation. The correct version of this news story can be read at https://www.thecerbatgem.com/2016/11/30/victory-capital-management-inc-takes-position-in-eagle-pharmaceuticals-inc-egrx.html.

A number of research firms have commented on EGRX. Mizuho downgraded shares of Eagle Pharmaceuticals from a “buy” rating to a “neutral” rating and set a $78.00 target price for the company. in a research report on Wednesday, November 16th. RBC Capital Markets reaffirmed an “outperform” rating and issued a $93.00 target price on shares of Eagle Pharmaceuticals in a research report on Monday, November 14th. Zacks Investment Research raised shares of Eagle Pharmaceuticals from a “strong sell” rating to a “buy” rating and set a $84.00 target price for the company in a research report on Friday, November 4th. Royal Bank Of Canada lifted their target price on shares of Eagle Pharmaceuticals from $80.00 to $93.00 and gave the stock an “outperform” rating in a research report on Thursday, November 3rd. Finally, William Blair lifted their target price on shares of Eagle Pharmaceuticals from $83.00 to $97.00 and gave the stock an “outperform” rating in a research report on Wednesday, November 2nd. Two investment analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the stock. The stock currently has an average rating of “Buy” and an average target price of $90.24.

In related news, major shareholder Proquest Investments Iv, L.P. sold 34,486 shares of the stock in a transaction that occurred on Friday, November 11th. The shares were sold at an average price of $85.15, for a total transaction of $2,936,482.90. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 18.80% of the company’s stock.

About Eagle Pharmaceuticals

Eagle Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses on developing and commercializing injectable products in the critical care and oncology areas. The Company’s product portfolio includes EP-1101 (argatroban); Ryanodex (dantrolene sodium); docetaxel injection, non-alcohol formulation (Non-Alcohol Docetaxel Injection); diclofenac-misoprostol; EP-3101 (Bendamustine Hydrochloride Injection, ready-to-dilute (RTD) concentrate solution), and EP-3102 (rapidly infused bendamustine RTD) (EP-3102 Bendeka).

5 Day Chart for NASDAQ:EGRX

Receive News & Stock Ratings for Eagle Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eagle Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.